What Infinimmune does
Infinimmune is a biotechnology company developing antibody therapeutics derived directly from the human immune system.[1] According to Infinimmune, its Anthrobody platform screens millions of single memory B cells across hundreds of targets to find natively paired, fully human antibodies, and its GLIMPSE antibody language models guide candidate selection and optimization.[1] Infinimmune is an Alameda biotech in the San Francisco Bay Area.[2],[3] Infinimmune's two lead programs are in atopic dermatitis: IFX-101, an antibody targeting IL-22, and IFX-201, an antibody targeting IL-13.[1] Infinimmune says it will begin first-in-human studies for both lead programs in 2027.[1]
Business model and customers
In March 2026, Infinimmune entered a multi-target antibody discovery collaboration with Merck that includes up to approximately $838 million in upfront and potential milestone payments.[1] In September 2025, KBI Biopharma announced a collaboration with Infinimmune to support antibody manufacturing.[2]
Leadership
- Wyatt McDonnell, Co-Founder and Chief Executive Officer[1]
- Katie Pfeiffer, Co-Founder and Chief Technology Officer[5]
- Mike Gibbons, Co-Founder and Chief Scientific Officer[5]
- Lance Hepler and David Jaffe, co-founders[3]
- Tim Sullivan, Chief Business Officer[5]
- Srikanth Pendyala, MD, Chief Medical Officer[5]
- Benjamin Kim, board director (Playground)[5]
Is this your company? Get featured or correct your listing →
Recent changes
- Aug 11, 2026Aug 11, 2026Raised $75M Series A Business Wire (via FinancialContent)
- Aug 11, 2026Aug 11, 2026New investor: Regeneron Ventures Business Wire (via FinancialContent)
- Aug 11, 2026Aug 11, 2026New investor: Godfrey Capital Business Wire (via FinancialContent)
- Aug 11, 2026Aug 11, 2026New investor: Playground Global Business Wire (via FinancialContent)
- Aug 11, 2026Aug 11, 2026New investor: Civilization Ventures Business Wire (via FinancialContent)
Earlier changes (4)
- Aug 11, 2026Aug 11, 2026New investor: Goldcrest Capital Business Wire (via FinancialContent)
- Aug 11, 2026Aug 11, 2026New investor: Pear VC Business Wire (via FinancialContent)
- Aug 11, 2026Aug 11, 2026New investor: RA Capital Business Wire (via FinancialContent)
- Aug 11, 2026Aug 11, 2026Infinimmune Raises $75M for Human-Derived Antibody Drugs Pulse story
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Aug 11, 2026 | Series A | $75M | — | Regeneron VenturesLeadMedCity NewsPlayground GlobalLeadunverifiedMerck Global Health Innovation FundMedCity NewsCivilization VenturesMedCity NewsPear VCMedCity NewsRA CapitalunverifiedGoldcrest CapitalunverifiedGodfrey CapitalunverifiedEverbright BiofundForge Life Science PartnersWild Tree Ventures | Pulse story |
How Infinimmune has been funded
In December 2022, Infinimmune closed a $12 million seed round led by Playground Global, with participation from Pear VC, Civilization Ventures and Axial VC, as reported by GEN.[3] On August 11, 2026, Infinimmune announced a $75 million Series A co-led by Regeneron Ventures and Playground Global.[1],[4] New Series A participants were RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital and Wild Tree Ventures, and existing investors Merck Global Health Innovation Fund, Everbright Biofund, Civilization Ventures and Pear VC also took part.[1] Infinimmune says the Series A will accelerate clinical development of its two lead atopic dermatitis programs.[1]
Investors and their roles
- Regeneron Ventures (co-led the Series A, Aug 2026)[1]
- Playground Global (led the $12M seed, Dec 2022; co-led the Series A, Aug 2026)[3],[1]
- RA Capital Management (participated in the Series A, Aug 2026)[1]
- Goldcrest Capital (participated in the Series A, Aug 2026)[1]
- Forge Life Science Partners (participated in the Series A, Aug 2026)[1]
- Godfrey Capital (participated in the Series A, Aug 2026)[1]
- Wild Tree Ventures (participated in the Series A, Aug 2026)[1]
- Merck Global Health Innovation Fund (existing investor; participated in the Series A, Aug 2026)[1]
- Everbright Biofund (existing investor; participated in the Series A, Aug 2026)[1]
- Civilization Ventures (seed, Dec 2022; Series A, Aug 2026)[3],[1]
- Pear VC (seed, Dec 2022; Series A, Aug 2026)[3],[1]
- Axial VC (seed, Dec 2022)[3]
Investors
Latest Pulse
Coverage Timeline
newest firstAll Coverage
Related Companies
Infinimmune FAQ
How much has Infinimmune raised?
Value Add VC tracks $87 million across 2 rounds for Infinimmune: a $12 million seed in December 2022 and a $75 million Series A in August 2026.[3],[1]
Who invested in Infinimmune?
Infinimmune's August 2026 Series A was co-led by Regeneron Ventures and Playground Global, with RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital, Wild Tree Ventures, Merck Global Health Innovation Fund, Everbright Biofund, Civilization Ventures and Pear VC participating.[1]
What does Infinimmune do?
Infinimmune develops antibody therapeutics derived from the human immune system, led by IFX-101 (IL-22) and IFX-201 (IL-13) for atopic dermatitis.[1]
Who founded Infinimmune?
Infinimmune was co-founded by Wyatt McDonnell, Katie Pfeiffer, Mike Gibbons, Lance Hepler and David Jaffe, as reported by GEN in December 2022.[3]
Who is the CEO of Infinimmune?
Wyatt McDonnell is Infinimmune's co-founder and CEO, according to its August 2026 Series A release.[1]
Is Infinimmune public?
Infinimmune raised a private Series A in August 2026, so it is privately held as of that date.[1]
References
researched 2026-10-19Sources & methodologyshow
Where these figures come from
- Business Wire (via FinancialContent)research database1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.